The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the holiday-shortened week before making a comeback.
William Blair Initiates Coverage On Intellia Therapeutics with Outperform Rating
William Blair analyst Raju Prasad initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Outperform rating.
How Have Cathie Wood’s Top 10 Investments Performed In The Last 6 Months?
Cathie Wood's ARK Invest ETFs are some of the hottest funds after 2020's huge stock market gains.
The ARK Innovation ETF (NYSE: ARKK) grew more than 152% in 2020, beating the Nasdaq's 43.6% return.
Brookline Capital Initiates Coverage On Intellia Therapeutics with Hold Rating
Brookline Capital initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Hold rating.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
$100 Invested In This Stock 5 Years Ago, Would Be Worth This Much
Intellia Therapeutics (NASDAQ:NTLA) has outperformed the market over the past 5 years by 33.15% on an annualized basis.
Cowen & Co. Initiates Coverage On Intellia Therapeutics with Outperform Rating
Cowen & Co. analyst Joseph Thome initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Outperform rating.